BREAKING NEWS

Third US patent on Israeli Teva's MS drug Copaxone invalidated

By REUTERS

SEPTEMBER 1, 2016 22:14

NEW YORK- US patent officials on Thursday invalidated a third patent covering Israel's Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment Copaxone, after canceling two other patents on the drug last week.

The ruling came in a challenge at the US Patent and Trademark Office by Mylan NV, which is trying to bring out a generic version of the 40-milligram injectable drug, taken three times a week. According to the US Food and Drug Administration, Copaxone is protected by five patents in total.

House arrest of intelligence officer involved in PMO document leak ends

By MAARIV

11/25/2024 01:58 PM

Lebanese army soldier killed in drone strike in Tyre - Al-Manar

By JERUSALEM POST STAFF

11/25/2024 01:41 PM

Russia's army bigger than two years ago but quality has decreased

By REUTERS

11/25/2024 01:17 PM

Security forces eliminate two terrorists, arrest nine in the West Bank

By JERUSALEM POST STAFF

11/25/2024 12:43 PM